These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 2595883

  • 1. Effect of systemic glutathione depletion by buthionine sulfoximine on sensitivity of murine bladder cancer to cytotoxic agents.
    Lee KE, Mayer RD, Cockett AT.
    Urology; 1989 Dec; 34(6):376-80. PubMed ID: 2595883
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of cisplatin-induced nephrotoxicity in rats by buthionine sulfoximine, a glutathione synthesis inhibitor.
    Mayer RD, Lee KE, Cockett AT.
    Cancer Chemother Pharmacol; 1987 Dec; 20(3):207-10. PubMed ID: 2890443
    [Abstract] [Full Text] [Related]

  • 3. Relationship between thiol depletion and chemosensitization in a transplantable murine bladder tumor.
    Tomashefsky P, Astor M, White RD.
    J Natl Cancer Inst; 1985 Jun; 74(6):1233-8. PubMed ID: 3858595
    [Abstract] [Full Text] [Related]

  • 4. Effects of glutathione depletion by buthionine sulfoximine on the sensitivity of EMT6/SF cells to chemotherapy agents or X radiation.
    Shrieve DC, Harris JW.
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1171-4. PubMed ID: 3744936
    [Abstract] [Full Text] [Related]

  • 5. Lack of enhanced antitumor efficacy for L-buthionine sulfoximine in combination with carmustine, cyclophosphamide, doxorubicin or melphalan in mice.
    Soble MJ, Dorr RT.
    Anticancer Res; 1988 Jul; 8(1):17-22. PubMed ID: 3358633
    [Abstract] [Full Text] [Related]

  • 6. Effects of buthionine sulfoximine treatment on cellular glutathione levels and cytotoxicities of cisplatin, carboplatin and radiation in human stomach and ovarian cancer cell lines.
    Lee KS, Kim HK, Moon HS, Hong YS, Kang JH, Kim DJ, Park JG.
    Korean J Intern Med; 1992 Jul; 7(2):111-7. PubMed ID: 1306072
    [Abstract] [Full Text] [Related]

  • 7. Differential sensitivities of murine melanocytes and melanoma cells to buthionine sulfoximine and anticancer drugs.
    Thrall BD, Raha GA, Springer DL, Meadows GG.
    Pigment Cell Res; 1991 Dec; 4(5-6):234-9. PubMed ID: 1823927
    [Abstract] [Full Text] [Related]

  • 8. Overcoming tumor necrosis factor-alpha resistance of human renal and ovarian carcinoma cells by combination treatment with buthionine sulfoximine and tumor necrosis factor-alpha. Role of tumor necrosis factor-alpha mRNA down-regulation in tumor cell sensitization.
    Mizutani Y, Yoshida O.
    Cancer; 1994 Feb 01; 73(3):730-7. PubMed ID: 8299097
    [Abstract] [Full Text] [Related]

  • 9. Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian-carcinoma cell lines.
    Mistry P, Loh SY, Kelland LR, Harrap KR.
    Int J Cancer; 1993 Nov 11; 55(5):848-56. PubMed ID: 8244583
    [Abstract] [Full Text] [Related]

  • 10. Combined effect of buthionine sulfoximine and cyclophosphamide upon murine tumours and bone marrow.
    Ono K, Komuro C, Tsutsui K, Shibamoto Y, Nishidai T, Takahashi M, Abe M, Shrieve DC.
    Br J Cancer; 1986 Nov 11; 54(5):749-54. PubMed ID: 3801271
    [Abstract] [Full Text] [Related]

  • 11. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer.
    O'Dwyer PJ, Hamilton TC, LaCreta FP, Gallo JM, Kilpatrick D, Halbherr T, Brennan J, Bookman MA, Hoffman J, Young RC, Comis RL, Ozols RF.
    J Clin Oncol; 1996 Jan 11; 14(1):249-56. PubMed ID: 8558205
    [Abstract] [Full Text] [Related]

  • 12. Enhancement of antitumor activity of cisplatin on human gastric cancer cells in vitro and in vivo by buthionine sulfoximine.
    Saikawa Y, Kubota T, Kuo TH, Furukawa T, Tanino H, Watanabe M, Ishibiki K, Kitajima M.
    Jpn J Cancer Res; 1993 Jul 11; 84(7):787-93. PubMed ID: 8370654
    [Abstract] [Full Text] [Related]

  • 13. Mitomycin C sensitivity in human bladder cancer cells: possible role of glutathione and glutathione transferase in resistance.
    Xu BH, Gupta V, Singh SV.
    Arch Biochem Biophys; 1994 Jan 11; 308(1):164-70. PubMed ID: 8311448
    [Abstract] [Full Text] [Related]

  • 14. In vivo therapeutic potential of combination thiol depletion and alkylating chemotherapy.
    Siemann DW, Beyers KL.
    Br J Cancer; 1993 Dec 11; 68(6):1071-9. PubMed ID: 8260357
    [Abstract] [Full Text] [Related]

  • 15. Depletion of tumour versus normal tissue glutathione by buthionine sulfoximine.
    Lee FY, Allalunis-Turner MJ, Siemann DW.
    Br J Cancer; 1987 Jul 11; 56(1):33-8. PubMed ID: 3620316
    [Abstract] [Full Text] [Related]

  • 16. Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells.
    Kisara S, Furusawa S, Murata R, Ogata M, Hikichi N, Takayanagi Y, Sasaki K.
    Oncol Res; 1995 Jul 11; 7(3-4):191-200. PubMed ID: 8555653
    [Abstract] [Full Text] [Related]

  • 17. Effect of glutathione depletion by L-buthionine sulfoximine on the cytotoxicity of cyclophosphamide in single and fractionated doses to EMT6/SF mouse tumors and bone marrow.
    Ono K, Shrieve DC.
    J Natl Cancer Inst; 1987 Oct 11; 79(4):811-5. PubMed ID: 3477662
    [Abstract] [Full Text] [Related]

  • 18. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine.
    Kramer RA, Greene K, Ahmad S, Vistica DT.
    Cancer Res; 1987 Mar 15; 47(6):1593-7. PubMed ID: 3815359
    [Abstract] [Full Text] [Related]

  • 19. Comparison of single agent cisplatin and cisplatin containing combinations in treatment of murine bladder cancer.
    Hickey DP, Brausi M, Blatnik AF, Soloway MS.
    Urology; 1987 Nov 15; 30(5):484-7. PubMed ID: 3118551
    [Abstract] [Full Text] [Related]

  • 20. Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO.
    Gallo JM, Brennan J, Hamilton TC, Halbherr T, Laub PB, Ozols RF, O'Dwyer PJ.
    Cancer Res; 1995 Oct 15; 55(20):4507-11. PubMed ID: 7553617
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.